uniQure (NASDAQ:QURE) Director Jack Kaye Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 1,993 shares of uniQure stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the sale, the director owned 25,996 shares in the company, valued at approximately $703,451.76. The trade was a 7.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Trading Up 2.8%

Shares of uniQure stock opened at $27.57 on Friday. The stock has a market cap of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The stock’s 50 day simple moving average is $22.52 and its 200-day simple moving average is $21.80. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts predict that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Barclays lowered their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Sanford C. Bernstein cut uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Wolfe Research assumed coverage on uniQure in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. Finally, Chardan Capital boosted their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new position in uniQure in the fourth quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its holdings in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in uniQure in the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC purchased a new stake in uniQure in the fourth quarter valued at approximately $48,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in uniQure in the third quarter valued at approximately $50,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.